Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is expected to see continued positive growth in their PYLARIFY and DEFINITY platforms, supported by the company's strong sales management and continued adoption of their products. PYLARIFY will continue with its smooth transition to its new formulation, TruVu, and the company is well-positioned for future growth with a strong pipeline of new products awaiting FDA approval. While risks related to reimbursement and regulation are present, the company's management has maintained a solid financial outlook for 2026 and beyond, mitigating concerns about potential disruptions to their business operations.

Bears say

Lantheus Holdings is heavily reliant on its pipeline of diagnostic agents and strategic partnerships, particularly for Alzheimer's disease, for future growth. However, the availability of therapeutic agents may affect the commercialization of these diagnostics, and it remains to be seen if these diagnostic agents will be positively received by the market. While the company's first quarter results were strong, management's cautious guidance for the rest of the year demonstrates potential hurdles and limits the potential for significant short-term gains.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.